ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO945

The Level of Poly-IgA Immune Complexes in the Short-Term Efficacy Evaluation and Disease Activity Monitoring of IgA Nephropathy (IgAN)

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Chen, Yulei, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China
  • Zhang, Xiao, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China
  • Luo, Yuxin, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China
  • Chen, Junzhe, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China
  • Tang, Ying, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China

Group or Team Name

  • Nephrology Dept.
Background

The formation of Poly-IgA immune complexes play a key role in IgAN. The levels of poly-IgA in IgAN were higher than those in healthy controls or in controls with non-IgAN disease. The changes of Poly-IgA in patients with IgAN are related to the severity of the disease. Whether Poly-IgA changes after treatment can evaluate the therapeutic effect, whether Poly-IgA level is an independent risk factor for non-remission, and whether it can be combined with other indicators to achieve a more accurate individual evaluation of IgAN patients still needs research.

Methods

74 IgAN patients in Department of Nephrology, The Third Affiliated Hospital of Southern Medical University from March 17, 2022 to March 28, 2023 were recorded. 54 individuals had been treated with corticosteroids or immunosuppressants. Paired-samples T test was used to compare the levels of Poly-IgA before and after treatment. 39 of them with proteinuria > 0.5g/ day at the beginning or after treatment were selected for short-term efficacy Evaluations. They were divided into two groups based on changes in urinary protein(UP) levels before and after treatment. Patients with UP level less than 0.5g/ d after treatment were classified as remission group, otherwise as non-remission group. Risk factors for its short-term efficacy were analyzed using logistic regression.

Results

54 IgAN patients were enrolled to compare the levels of Poly-IgA before and after treatment. We found out that the levels of Poly-IgA before treatment (Mean=18.91, SD=3.73) was significantly higher than that after treatment (Mean=14.24, SD=10.49), (P=0.01). The multivariate logistic regression identified that for every 0.306 increase in levels of Poly-IgA after treatment, the risk of disease progression in IgAN patients increased by 35.8%(P=0.022).

Conclusion

The findings suggest that elevated Poly-IgA levels after treatment are associated with an increased risk of non-remission in IgAN patients.Therefore, monitoring Poly-IgA level can be used as a valuable biomarker to evaluate the efficacy of IgAN. Further studies are needed in the future to validate these findings and to explore the potential of combining Poly-IgA with other measures to construct and optimize models for evaluating short - and long-term outcomes in IgAN patients to more accurately personalize the assessment of IgAN patients.